A randomized single-blind controlled trial of piperacillin/sulbactam and piperacillin/tazobactam in treatment of bacterial infections

AIM: To evaluate the efficacy and safety of piperacillin/sulbactam in the treatment of bacterial infections. METHODS: Seventy-seven patients with bacterial infections were selected in this study including 38 patients enrolled in piperacillin/sulbactam group(M 9,F 29;age(38±s 16) a) with 37 patients assessed for efficacy and all of the members for safety; and other 39 patients enrolled in piperacillin/tazobactam group(M 16, F 23;age (38±16) a) with 38 of them assessed for efficacy and totally for safety. Under the conduction of a randomized single-blind control trial, the daily dosages were 10-20 g for piperacillin/sulbactam and 9-18 g for piperacillin/tazobactam 5 % glucose or 0.9 % sodium chloride injection 100 mL containing 13 dosage of the forementioned drugs was administrated through intravenous infusion for three times within the whole course of 5-14 d, respectively for each group. RESULTS: The clinical efficacy rates were 97 % for both piperacillin/sulbactam group and piperacillin/tazobactam group. The bacterial efficacy rates were 96 % and 100 %, together with the susceptibility rates of 98 % and 100 %, respectively for each. Adverse reaction rates were 5 % equally for both groups. CONCLUSION: The results show that piperacillin/sulbactam combination is effective and safe in the treatment of bacterial infections.